Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA) (PROVE-FA)
Evaluation of Long-Term Efficacy of Vatiquinone for the Treatment of Friedreich's Ataxia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Patient Advocacy
- Phone Number: 1-866-562-4620
- Email: medinfo@ptcbio.com
Study Locations
-
-
-
Brussels, Belgium, 1070
- Hôpital Érasme (Hôpital Universitaire de Bruxelles)
-
Principal Investigator:
- Gilles Naeije
-
-
-
-
São Paulo
-
Campinas, São Paulo, Brazil, 13083-888
- University of Campinas
-
Principal Investigator:
- Marcondes França
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0A9
- Centre Hospitalier de l'Universite de Montreal CHUM
-
Principal Investigator:
- Antoine Duquette
-
-
-
-
-
Paris, France, 75013
- Institut du Cerveau et de la Moelle Epinière
-
Principal Investigator:
- Alexandra Durr
-
-
-
-
-
Barcelona, Spain, 08950
- Hospital Sant Joan de Déu
-
Principal Investigator:
- Alejandra Darling
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- University of California Los Angeles
-
Principal Investigator:
- Susan Perlman
-
-
Florida
-
Tampa, Florida, United States, 33612
- University of South Florida
-
Principal Investigator:
- Theresa Zesiewicz
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
Principal Investigator:
- Katherine Mathews
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
Principal Investigator:
- David Lynch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- mFARS ≥20 to ≤70 at Screening (4 weeks prior to Day 1) and Baseline (Day 1).
- Must be ambulatory as defined by a E7 score of 4 or less on the USS at Screening and Baseline.
- Documentation that participants reached maximum score on items E4, E5, and E3b on the USS of mFARS at Screening and Baseline.
- FA diagnosis (homozygous for guanine-adenine-adenine [GAA] repeat expansion in intron-1 of the frataxin gene), confirmed and documented with GAA repeat length for both alleles by clinical genetic testing.
- Difference in the mFARS score between Screening and Baseline of no more than 4 points.
- Ability to abstain from strong cytochrome P450 (CYP) 3A4 inducers/inhibitors (for example, ketoconazole, rifampin, St. John's wort, grapefruit juice) for at least 4 weeks prior to Baseline and for the duration of the study.
Key Exclusion Criteria:
- Individuals with clinical diagnosis of FA who have point mutations, deletions, or other non-GAA expansion mutations.
- Allergy to vatiquinone, sesame oil, gelatin (bovine and/or porcine), titanium dioxide, or red iron oxide.
- Pregnant or lactating participants or those sexually active participants who are unwilling to comply with proper birth control methods; females of childbearing potential must have a negative pregnancy test at Screening and during the Baseline Visit.
- Comorbidities that may confound study results (for example, fat malabsorption syndrome, other mitochondrial disorder) in the opinion of the investigator.
- Participation in an interventional clinical study or received investigational drug (other than SKYCLARYS® [omaveloxolone]) within 60 days prior to Screening. Participants may be screened after the exclusionary period of 60 days has passed.
Current use of omaveloxolone. Previous use of omaveloxolone will be allowed if:
- Use was less than 3 cumulative months and participants have been off treatment for >30 days.
- Use was less than 6 cumulative months and participants have been off treatment for >90 days
- Previous or concurrent use of other investigational treatment for FA.
- Participation in any cell or gene therapy-based treatment for FA.
- Participation in an ongoing study for vatiquinone or current or previous use of vatiquinone.
- Illicit drug use 30 days prior to Screening and during the study.
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vatiquinone
Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if weighing ˂25 kilograms (kg) or 400 mg orally TID if weighing ≥25 kg for 24 months.
|
Vatiquinone will be administered per dose and schedule specified in the arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in Total Modified Friedreich's Ataxia Rating Scale (mFARS) Score at Month 24
Time Frame: Baseline, Month 24
|
Baseline, Month 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in mFARS Subscale Scores (Upright Stability Subscale [USS], Upper Limb [UL], Lower Limb [LL], Bulbar [BUL]) at Month 24
Time Frame: Baseline, Month 24
|
Baseline, Month 24
|
|
Change From Baseline in Friedreich's Ataxia Rating Scale - Activities of Daily Living (FARS-ADL) Score at Month 24
Time Frame: Baseline, Month 24
|
Baseline, Month 24
|
|
Change From Baseline in 25-Foot Walk Test (T25FW) at Month 24
Time Frame: Baseline, Month 24
|
Baseline, Month 24
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Baseline up to Month 25
|
Baseline up to Month 25
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Metabolic Diseases
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Spinal Cord Diseases
- Mitochondrial Diseases
- Cerebellar Diseases
- Spinocerebellar Degenerations
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Friedreich Ataxia
- alpha-tocotrienol quinone
Other Study ID Numbers
Other Study ID Numbers
- PTC743-FA-304
- 2026-526947-37-00 (Ctis)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.